Estrella Immunopharma, INC 10-Q quarterly reports

Estrella Immunopharma's Q2 2026 report highlights significant R&D expenses and a substantial accumulated deficit, leading to a going concern warning despite recent capital raises.

Estrella Immunopharma, a clinical-stage biopharmaceutical company, reported increased net losses and expenses for Q3 2025, while advancing its STARLIGHT-1 clinical trial and addressing internal control weaknesses.

Estrella Immunopharma reported increased net losses and a growing accumulated deficit, receiving two Nasdaq non-compliance notices for minimum bid price and market value of listed securities.

Estrella Immunopharma's Q1 2025 results show a net loss of $2.1 million, driven by increased research and development expenses related to its T-cell therapy programs.

Estrella Immunopharma's Q1 2025 report reveals a net loss of $3.4 million, driven by increased research and development expenses, as the company continues to advance its T-cell therapy programs.

Estrella Immunopharma reported a net loss of $0.5 million for the first quarter of 2024, while advancing preparations for its Starlight-1 clinical trial.

Estrella Immunopharma reports its financial results for the quarter ended December 31, 2023, following its business combination and detailing its ongoing development of T-cell therapies.